Evidence map›Paper›PMID 37889444›Full record

ArticleJournal of neuro-oncology2023

Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients.

Eric J Lehrer, Atulya A Khosla, Ahmad Ozair, Jason Gurewitz, Kenneth Bernstein, Douglas Kondziolka, Ajay Niranjan, Zhishuo Wei, L Dade Lunsford, David Mathieu and 24 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 13 institutions in 4 countries.

Eric J Lehrer *Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. lehrer.eric@mayo.edu.
Atulya A Khosla *Department of Medical Oncology, Miami Cancer Institute, Miami, FL, USA.
Ahmad Ozair *Department of Medical Oncology, Miami Cancer Institute, Miami, FL, USA.
Jason GurewitzDepartment of Radiation Oncology, NYU Langone Medical Center, New York, NY, USA.
Kenneth BernsteinDepartment of Radiation Oncology, NYU Langone Medical Center, New York, NY, USA.
Douglas KondziolkaDepartment of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
Ajay NiranjanDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Zhishuo WeiDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
L Dade LunsfordDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
David MathieuDepartment of Neurosurgery, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, QC, Canada.
Claire TrudelDepartment of Medicine, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, QC, Canada.
Christopher P DeibertDepartment of Neurological Surgery, Emory University, Atlanta, GA, USA.
Timothy D MalouffDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Henry Ruiz-GarciaDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Jennifer L PetersonDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Samir PatelDivision of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada.
Phillip BonneyDepartment of Neurosurgery, University of Southern California, Los Angeles, CA, USA.
Lindsay HwangDepartment of Radiation Oncology, University of Southern California, Los Angeles, CA, USA.
Cheng YuDepartment of Neurosurgery, University of Southern California, Los Angeles, CA, USA.
Gabriel ZadaDepartment of Neurosurgery, University of Southern California, Los Angeles, CA, USA.
Piero PicozziDepartment of Neurosurgery, IRCCS Humanitas Research Hospital, Rozzano (Mi), Italy.
Andrea FranziniDepartment of Neurosurgery, IRCCS Humanitas Research Hospital, Rozzano (Mi), Italy.
Luca AttuatiDepartment of Neurosurgery, IRCCS Humanitas Research Hospital, Rozzano (Mi), Italy.
Rahul N PrasadDepartment of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Raju R RavalDepartment of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Joshua D PalmerDepartment of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Cheng-Chia LeeDepartment of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan.
Huai-Che YangDepartment of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan.
Kareem R FakhouryDepartment of Radiation Oncology, University of Colorado, Denver, CO, USA.
Chad G RusthovenDepartment of Radiation Oncology, University of Colorado, Denver, CO, USA.
Daniel R DicksteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jason P SheehanDepartment of Neurological Surgery, University of Virginia, Charlottesville, VA, USA.
Daniel M TrifilettiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Manmeet S AhluwaliaDepartment of Medical Oncology, Miami Cancer Institute, Miami, FL, USA.
Mayo Clinic in Florida · USUniversity of Southern California · USIRCCS Humanitas Research Hospital · ITNeurological Surgery · USNYU Langone Health · USThe Ohio State University Wexner Medical Center · USTaipei Veterans General Hospital · TWUniversité de Sherbrooke · CAUniversity of Colorado Denver · USUniversity of Pittsburgh Medical Center · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeApproximately 80% of brain metastases originate from non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) and stereotactic radiosurgery (SRS) are frequently utilized in this setting. However, concerns remain regarding the risk of radiation necrosis (RN) when SRS and ICI are administered concurrently.

methodsA retrospective study was conducted through the International Radiosurgery Research Foundation. Logistic regression models and competing risks analyses were utilized to identify predictors of any grade RN and symptomatic RN (SRN).

resultsThe study included 395 patients with 2,540 brain metastases treated with single fraction SRS and ICI across 11 institutions in four countries with a median follow-up of 14.2 months. The median age was 67 years. The median margin SRS dose was 19 Gy; 36.5% of patients had a V12 Gy ≥ 10 cm

conclusionThe risk of any grade RN and symptomatic RN following single fraction SRS and ICI for NSCLC brain metastases increases as V12 Gy exceeds 10 cm

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryAgedHumansImmune Checkpoint InhibitorsRetrospective StudiesImmune Checkpoint InhibitorsBrain neoplasmsCombined modality therapyImmune checkpoint inhibitorsNon-small cell lung cancerRadiation injuriesRadiosurgery

Identifiers

PMID37889444
OpenAlexW4387965452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.